|
Design and efficacy of L-CapA-L-CapC Anticancer-L-RIb-Streptococcus agalactiae fusion protein against COVID-19
|
Elmira Babakanrad   , Taher Mohamadian *  , Davoud Esmaeili , Payam Behzadi |
| Department of Microbiology, Shahr-e-Qods Branch, Islamic Azad University, Tehran, Iran , tmohammadian@qodsiau.ac.ir |
|
|
Abstract: (1561 Views) |
Background and Aim: SARS-CoV-2 was identified in late 2019 as a respiratory disease agent called COVID-19. Several drug therapies have been studied to treat COVID-19, none of which have had a definite effect so far. In mild cases of the disease, treatment is careful to reduce the symptoms of the disease, and in severe cases, the patient must be hospitalized to receive different treatments. There are several medications available, many of which are still being evaluated, and there is still no definitive cure for COVID-19
Methods: In this study, an attempt is made to investigate various treatment methods, including the use of L-CapA-L-CapC Anticancer-L-Rib-fusion protein in the treatment of COVID-19 in terms of bioinformatics. In this study, the use of bacterial peptides antiviral drugs is emphasized to introduce appropriate treatment to control SARS-CoV-2
Results: L-CapA-L-CapC Anticancer-L-Rib- fusion protein and Spike virus sequences were extracted using NCBI database. Then, using various software such as SWISS-MODEL and Expasy, the structural model of the protein and its quality were determined. The immunogenicity of L-CapA-L-CapC Anticancer-L-Rib fusion protein was also evaluated.
Conclusion: Based on the bioinformatics results, L-CapA-L-CapC Anticancer-L-Rib fusion protein has a dense and complex structure and in addition to its anti-cancer and anti-viral properties, it can be used in the treatment of COVID-19. |
|
| Keywords: Coronavirus, COVID-19, Bioinformatics, Antibiotics. |
|
|
Full-Text [PDF 910 kb]
(700 Downloads)
|
Type of Study: Original Article |
Subject:
Marine Medicine
Received: 2021/08/25 | Accepted: 2021/08/31 | Published: 2021/09/1
|
|
|
|
|
|
